The global interleukin inhibitors market size was estimated at USD 20.7 billion in 2018 and is expected to exhibit a CAGR of 17.4% during the forecast period. Growing prevalence of autoimmune diseases and increasing adoption of interleukin inhibitors are expected to drive the IL Inhibitors market growth. There has been a significant paradigm shift in the treatment of autoimmune diseases over the last few decades. The preference for targeted therapies is increasing due to their improved safety and efficacy profiles. Patent expiry and increased adoption of biosimilar Tumor Necrosis Factor (TNF) inhibitors has raised the growth potential of the market.